equipment and other medical supplies necessary to prepare for and respond to a pandemic and all reasonable alternatives for mitigating such vulnerabilities in future pandemics. (15) Evaluating the contribution of the Defense Production Act in the COVID–19 emergency and whether this law should be amended to improve pandemic preparedness and response. (16) Evaluating the National Stockpile in preparing for and responding to pandemics, the performance of the National Stockpile in responding to the COVID–19 emergency, and all reasonable alternatives improving the management and contributions of the Stockpile in preparing for and responding to future pandemics. (17) Evaluating the role of the Federal Government in developing and approving surveillance, testing, treatments, therapeutics and vaccines for COVID–19 and all reasonable alternatives to improve the development of therapeutics and vaccines in future pandemics. (18) Evaluating the Federal, State, and local response to the COVID–19 emergency related to ensuring adequate national surge capacity infrastructure in hospitals and medical centers and alternatives for improving such preparedness and response to ensure adequate capacity in future pandemics. (19) Identifying and evaluating the array of public health interventions at the Federal, State, and local levels, including mask orders, social distancing practices, stay-at-home directives, school and business closures, and other measures, implemented in response to the COVID–19 emergency and evaluating all reasonable alternatives for improving such public health responses in future pandemics with a due consideration of the economic and other public health costs and tradeoffs associated with such measures. (20) Evaluating the performance of financial markets and regulators during the COVID–19 emergency. (21) Evaluating the overall efficacy of the Federal economic response to the COVID–19 emergency and recommendations for modifying those responses to improve preparedness and response to future pandemics. (22) Any